Literature DB >> 345893

Bovine antibody against Streptococcus agalactiae, type Ia, produced by preparturient intramammary and systemic vaccination.

Y Yokomizo, N L Norcross.   

Abstract

Four pregnant heifers were immunized by the intramammary route with killed or live Streptococcus agalactiae vaccine, and a 5th heifer was vaccinated by the intramuscular route with killed vaccine. Antibody in the colostrum from vaccinated and non-vaccinated glands was compared. Antibacterial glands was compared. Antibacterial antibody titers of the 4 immunoglobulin classes were determined by indirect fluorescent antibody assay. Although the content of immunoglobulin G1 (IgG1), IgG2, and IgM in the colostrum from the vaccinated glands was not substantially different from the nonvaccinated glands, IgA content was considerably greater in the former. Antibody specific to S agalactiae was isolated from all colostrum samples. The mouse passive protection test and Ouchterlony analysis were used to demonstrate the presence of type-specific antibody to Ia strain used for vaccination. The passive mouse protection test also was useful to compare the protective capacity of specific S agalactiae, type Ia, antibodies of immunoglobulin classes IgG, IgM, and IgA. Increased protective capacity of IgM and IgA over IgG1, on a weight basis, was demonstrated. The present study indicates that S agalactiae preparations, when introduced into the mammary gland, can give rise to local antibody synthesis in the vaccinated glands.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 345893

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  2 in total

1.  Variation of type antigens of group-B streptococci. II. Studies on the in-vitro variation of the X-antigen and other type antigens.

Authors:  N E Jensen; B Berg
Journal:  Acta Vet Scand       Date:  1980       Impact factor: 1.695

2.  Immune response in the bovine mammary gland after intestinal, local, and systemic immunization.

Authors:  C C Chang; A J Winter; N L Norcross
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.